CFR-PEEK Pedicle Screw Instrumentation for Spinal Neoplasms: A Single Center Experience on Safety and Efficacy.
CFR-PEEK
CFRP
carbon reinforced polyethyl-ether-ether-ketone
neuro-oncology
spinal metastases
spinal primary bone tumors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Oct 2022
27 Oct 2022
Historique:
received:
10
09
2022
revised:
16
10
2022
accepted:
26
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
(1) Background: Surgery for spinal metastases has gained a decisive role in modern oncological treatment. Recently, carbon-fiber-reinforced (CFR) polyethyl-ether-ether-ketone (PEEK) pedicle screw systems were introduced, reducing artifacts on imaging and showing less perturbation effects on photon radiation. Preliminary clinical experience with CFR-PEEK implants for spinal metastases exists. The aim of this monocentric study is to report on the safety and efficacy of CFR-PEEK pedicle screw systems for spinal neoplasms in a large cohort of consecutive patients. (2) Methods: We retrospectively analyzed prospectively the collected data of consecutive patients being operated on from 1 August 2015 to 31 October 2021 using a CFR-PEEK pedicle screw system for posterior stabilization because of spinal metastases or primary bone tumors of the spine. (3) Results: We included 321 patients of a mean age of 65 ± 13 years. On average, 5 ± 2 levels were instrumented. Anterior reconstruction was performed in 121 (37.7%) patients. Intraoperative complications were documented in 30 (9.3%) patients. Revision surgery for postoperative complications was necessary in 55 (17.1%) patients. Implant-related complications, such as intraoperative screw breakage (3.4%) and screw loosening (2.2%), were rare. (4) Conclusions: CFR-PEEK is a safe and efficient alternative to titanium for oncological spinal instrumentation, with low complication and revision rates in routine use and with the advantage of its radiolucency.
Identifiants
pubmed: 36358693
pii: cancers14215275
doi: 10.3390/cancers14215275
pmc: PMC9658073
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int Orthop. 2007 Apr;31(2):259-64
pubmed: 16783550
Eur Spine J. 2018 Apr;27(4):874-881
pubmed: 28815357
Sci Rep. 2021 Apr 12;11(1):7988
pubmed: 33846484
Neurosurg Rev. 2021 Aug;44(4):2163-2170
pubmed: 32930911
World Neurosurg. 2021 Jul;151:e495-e506
pubmed: 33905911
Sci Rep. 2021 Jan 28;11(1):2414
pubmed: 33510239
Lancet. 2005 Aug 20-26;366(9486):643-8
pubmed: 16112300
Neurosurg Focus. 2021 May;50(5):E13
pubmed: 33932921
Eur Spine J. 2018 Aug;27(8):1775-1784
pubmed: 29497852
World Neurosurg. 2021 Oct;154:e536-e546
pubmed: 34339894
Adv Orthop. 2020 Jun 09;2020:4796136
pubmed: 32566313
Eur Spine J. 2021 Dec;30(12):3720-3730
pubmed: 34519911
Acta Neurochir (Wien). 1990;107(1-2):37-43
pubmed: 2096606
Sci Rep. 2020 Sep 30;10(1):16094
pubmed: 32999385
Dtsch Arztebl Int. 2011 Feb;108(5):71-9; quiz 80
pubmed: 21311714
Curr Oncol. 2021 Oct 02;28(5):3891-3899
pubmed: 34677250
J Clin Neurosci. 2020 May;75:106-111
pubmed: 32173153
J Neurosurg Spine. 2010 Aug;13(2):144-57
pubmed: 20672949
Brain Spine. 2022 Feb 26;2:100875
pubmed: 36248120
J Bone Oncol. 2022 Jul 09;35:100446
pubmed: 35860387
Acta Neurochir (Wien). 2020 Apr;162(4):943-950
pubmed: 31953690
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Neurosurg Focus. 2021 May;50(5):E7
pubmed: 33932937
World Neurosurg. 2017 Sep;105:294-301
pubmed: 28478252
Cancers (Basel). 2022 Apr 30;14(9):
pubmed: 35565376
World Neurosurg. 2021 Apr;148:e264-e274
pubmed: 33418123
Clin Spine Surg. 2017 Feb;30(1):4-13
pubmed: 27984252
J Clin Oncol. 2016 Sep 1;34(25):3054-61
pubmed: 27400936
J Appl Clin Med Phys. 2017 Mar;18(2):62-68
pubmed: 28300369
Spine (Phila Pa 1976). 1990 Jan;15(1):1-4
pubmed: 2326692
J Clin Oncol. 2016 Jan 20;34(3):268-76
pubmed: 26598751
Phys Med Biol. 2017 Apr 21;62(8):R49-R80
pubmed: 28323641